c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells

被引:58
作者
Ceballos, E
Delgado, MD
Gutierrez, P
Richard, C
Müller, D
Eilers, M
Ehinger, M
Gullberg, U
León, J
机构
[1] Hosp Marques de Valdecilla, Serv Hematol, Santander, Spain
[2] Univ Marburg, Inst Mol Biol & Tumor Res, Marburg, Germany
[3] Lund Univ, Dept Hematol, Lund, Sweden
关键词
myc; p53; leukemia; K562; apoptosis; transactivation;
D O I
10.1038/sj.onc.1203541
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
c-myc protooncogene positively regulates cell proliferation and overexpression of c-myc is found in many solid tumors and leukemias, In the present study we used the K562 human myeloid leukemia cell line as a model to study the functional interaction between c-Myc and p53. Using two different methods, we generated K562 transfectant cell lines with conditional expression of either c-Myc or p53. The cells expressed the p53(Vall35) mutant, which adopts a mild-type conformation at 32 degrees C, while c-Myc induction was achieved with a zinc-inducible expression vector. We found that p53 in mild-type conformation induces growth arrest and apoptosis of K562. Expression of c-Myc significantly attenuated apoptosis and impaired the transcriptional activity of D53 on p21(WAF1), fax and cytomegalovirus promoters. The impairment of p21(WAF1) transactivation by c-Myc was confirmed by transfection of a c-Myc-estrogen receptor fusion protein and by induction of c-myc by zinc in transfected cells. Also, p53-mediated up-regulation of p21(WAF1) mRNA protein mere significantly reduced by Myc, while Bas levels were unaffected. Consistently, c- Myc increased cyclin-dependent kinase 2 activity in K562 cells expressing p53 in wild-type conformation These results suggest that c-Myc overexpression may antagonize the pro-apoptotic function of p53, thus providing a molecular mechanism for frequently observed deregulation of c-myc in human cancer.
引用
收藏
页码:2194 / 2204
页数:11
相关论文
共 90 条
[1]  
Adachi J, 1996, CELL GROWTH DIFFER, V7, P879
[2]   THE SPECTRUM OF MOLECULAR ALTERATIONS IN THE EVOLUTION OF CHRONIC MYELOCYTIC-LEUKEMIA [J].
AHUJA, H ;
BARELI, M ;
ARLIN, Z ;
ADVANI, S ;
ALLEN, SL ;
GOLDMAN, J ;
SNYDER, D ;
FOTI, A ;
CLINE, M .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) :2042-2047
[3]  
Alarcon RM, 1996, CANCER RES, V56, P4315
[4]   THE KARYOTYPE OF BLASTIC CRISIS [J].
ALIMENA, G ;
DECUIA, MR ;
DIVERIO, D ;
GASTALDI, R ;
NANNI, M .
CANCER GENETICS AND CYTOGENETICS, 1987, 26 (01) :39-50
[5]  
AMATI B, 1998, FRONT BIOSCI, V3, pD520
[6]   Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress [J].
Amundson, SA ;
Myers, TG ;
Fornace, AJ .
ONCOGENE, 1998, 17 (25) :3287-3299
[7]   Mechanisms of p53-mediated apoptosis [J].
Bates, S ;
Vousden, KH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :28-37
[8]   Changes in oncogene expression implicated in evolution of chronic granulocytic leukemia from its chronic phase to acceleration [J].
Beck, Z ;
Bácsi, A ;
Kovács, E ;
Kiss, J ;
Kiss, A ;
Balogh, E ;
Telek, B ;
Tóth, FD ;
Andirkó, I ;
Oláh, E ;
Udvardy, M ;
Rak, K .
LEUKEMIA & LYMPHOMA, 1998, 30 (3-4) :293-306
[9]   REGULATED EXPRESSION OF P150,95 (CD11C/CD18 ALPHA-X/BETA-2) AND VLA-4 (CD49D/CD29 ALPHA-4/BETA-1) INTEGRINS DURING MYELOID CELL-DIFFERENTIATION [J].
BELLON, T ;
LOPEZRODRIGUEZ, C ;
RUBIO, MA ;
JOCHEMS, G ;
BERNABEU, C ;
CORBI, AL .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (01) :41-47
[10]  
BERNS EMJJ, 1992, CANCER RES, V52, P1107